BioCentury | Mar 26, 2021
Finance

Valuations spiral into billions as trio of IPOs post big aftermarket gains: Data Byte

...three biopharmas to go public ahead of trading Friday, alongside Edgewise Therapeutics Inc. (NASDAQ:EWTX) and Ikena Oncology Inc....
...during the first quarter, according to BioCentury’s BCIQ database. Paul Bonanos Design Therapeutics Inc. Edgewise Therapeutics Ikena Oncology Edgewise Therapeutics Inc. Ikena Oncology Inc....
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...has a clinical development team based in Shanghai.Ikena Oncology Inc....
...Funds as the leader. Previously known as Kyn...
BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...medical head, immunology and specialty medicine franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Zdravkovic is pursuing new opportunities. Ikena Oncology Inc....
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...2018 to 2019 include ARG1, which dropped from eight mentions to one this year, and KYN...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Berman as head of R&D in September 2018 and Bahija Jallal as CEO in January. Kyn...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...was VP of quality solids Americas and special technologies at Novartis AG (NYSE:NVS; SIX:NOVN). Immuno-oncology Kyn...
BioCentury | Feb 1, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 29, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 25, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...Cambridge, Mass. Business: Cancer Karen Tkach Tuzman AhR Pharmaceuticals Inc. Obsidian Therapeutics Inc. Bristol Myers Squibb Co. Celgene Corp. Ikena Oncology Inc. Interleukin-12 (IL-12) Kynurenine (KYN) CD40L immuno-metabolism...
BioCentury | Jan 19, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...enzyme that degrades immunosuppressive metabolite kynurenine, and the other an antagonist of kynurenine receptor AHR. Kyn...
Items per page:
1 - 10 of 22
BioCentury | Mar 26, 2021
Finance

Valuations spiral into billions as trio of IPOs post big aftermarket gains: Data Byte

...three biopharmas to go public ahead of trading Friday, alongside Edgewise Therapeutics Inc. (NASDAQ:EWTX) and Ikena Oncology Inc....
...during the first quarter, according to BioCentury’s BCIQ database. Paul Bonanos Design Therapeutics Inc. Edgewise Therapeutics Ikena Oncology Edgewise Therapeutics Inc. Ikena Oncology Inc....
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...has a clinical development team based in Shanghai.Ikena Oncology Inc....
...Funds as the leader. Previously known as Kyn...
BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...medical head, immunology and specialty medicine franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Zdravkovic is pursuing new opportunities. Ikena Oncology Inc....
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...2018 to 2019 include ARG1, which dropped from eight mentions to one this year, and KYN...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Berman as head of R&D in September 2018 and Bahija Jallal as CEO in January. Kyn...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...was VP of quality solids Americas and special technologies at Novartis AG (NYSE:NVS; SIX:NOVN). Immuno-oncology Kyn...
BioCentury | Feb 1, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 29, 2019
Company News

Celgene gains option for Triphase's epigenetic cancer therapy

...is at least its third option deal since, with the bellwether recently announcing deals with Kyn...
...Cambridge, Mass.) (see "Bristol-Myers' Next Phoenix Act?" and "Celgene Bolsters Immuno-Metabolism, Immune Cell Toolbox with Kyn...
BioCentury | Jan 25, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...Cambridge, Mass. Business: Cancer Karen Tkach Tuzman AhR Pharmaceuticals Inc. Obsidian Therapeutics Inc. Bristol Myers Squibb Co. Celgene Corp. Ikena Oncology Inc. Interleukin-12 (IL-12) Kynurenine (KYN) CD40L immuno-metabolism...
BioCentury | Jan 19, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

...Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week...
...billion in a cash and stock deal (see "Bristol-Myers' Next Phoenix Act?" ). Through the Kyn...
...enzyme that degrades immunosuppressive metabolite kynurenine, and the other an antagonist of kynurenine receptor AHR. Kyn...
Items per page:
1 - 10 of 22